Scancell Holdings plc
("Scancell" or the
"Company")
Notice of Interim
Results
Scancell Holdings plc (AIM: SCLP), a
clinical-stage biopharmaceutical company developing novel
immunotherapies for cancer, will announce its interim results for
the six months ended 31 October 2024 on Thursday 30 January
2025.
Dr Phil L'Huillier, Chief Executive Officer,
and Sath Nirmalananthan, Chief Financial Officer, will host a
virtual analyst briefing at 14:00 GMT on the day of the results.
There will also be a live webcast and conference call with a
Q&A session, which can be accessed via this link:
https://www.lsegissuerservices.com/spark/ScancellHoldings/events/ed5646ee-d413-404a-8a95-73bfef540393.
A copy of the presentation and webcast will be
shared on the Investor Relations section of the Company's website
at https://scancell.co.uk/
shortly afterwards.
-ENDS-
For further
information, please contact:
Scancell
Holdings plc
+44 (0) 20 3709 5700
Phil L'Huillier, CEO
Sath Nirmalananthan, CFO
Professor Lindy Durrant, CSO
Dr Jean-Michel Cosséry, Non-Executive
Chairman
Panmure
Liberum Limited (Nominated Advisor and Joint Broker)
+44
(0) 20 7886 2500
Emma Earl/ Will Goode/ Mark Rogers (Corporate
Finance)
Rupert Dearden (Corporate Broking)
WG Partners
LLP (Joint Broker)
+44
(0) 20 3705 9330
David Wilson/ Claes Spang/ Satheesh
Nadarajah
ICR Healthcare
+44
(0) 20 37095700
Mary-Jane Elliott/ Angela Gray/ Lindsey Neville
scancell@icrhealthcare.com
About
Scancell
Scancell is a clinical stage biopharmaceutical
company that is leveraging its proprietary research, built up over
many years of studying the human adaptive immune system, to
generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope® and
ImmunoBody® for vaccines and GlyMab® and AvidiMab® for
antibodies.
Adaptive immune responses include antibodies
and T cells (CD4 and CD8), both of which can recognise damaged or
infected cells. In order to destroy such cancerous or infected
cells, Scancell uses either vaccines to induce immune responses or
monoclonal antibodies (mAbs) to redirect immune cells or drugs. The
Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope®
and ImmunoBody®) this includes citrullination and
homocitrullination of proteins, whereas its mAb portfolio targets
glycans or sugars that are added onto proteins and / or lipids
(GlyMab® ) or enhances the potency of antibodies and their ability
to directly kill tumour cells (AvidiMab® ).
For further information about Scancell, please
visit: https://www.scancell.co.uk/
